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A hallmark of protective immunity during Mycobacterium
tuberculosis (M. tb) infection is the regulated secretion of pro-
inflammatory and regulatory cytokines. Suppressors of Cyto-
kine Signaling (SOCS) are key regulators of cytokine secre-
tion and function. In this study we investigated regulation of
Toll-like receptor 2 (TLR2) and dendritic cell-specific
ICAM-3 grabbing non-integrin receptor 1 (DC-SIGNR1)-me-
diated SOCS1 expression in DCs during M. tb infection. We
show that, compared with TLR2, stimulating DC-SIGNR1 on
DCs induces higher SOCS1 expression and lower interleu-
kin-12 production. Co-stimulating DC-SIGNR1 and TLR2
differentially regulates SOCS1 expression depending on the
relative concentration of their ligands. Stimulating
DC-SIGNR1 with M. tb infection increases SOCS1 expres-
sion, while stimulating TLR2 with M. tb infection reduces
SOCS1 expression. Knockdown of SOCS1 in DCs by siRNA
enhances interleukin-12 transcription and protein expres-
sion upon DC-SIGNR1 stimulation. Raf-1 and Syk differen-
tially regulate TLR2- and DC-SIGNR1-mediated SOCS1
expression. In addition, DC-SIGNR1 shows greater associa-
tion with SOCS1 when compared with TLR2. Interestingly,
compared with healthy asymptomatic individuals, peripheral
bloodmononuclear cells of patientswith active tuberculosis dis-
ease showed higher expression of SOCS1, which was reduced
following chemotherapy. Similarly, stimulating DC-SIGNR1 on
DCs from M. tb-infected TLR2/ mice enhanced SOCS1
expression that was reduced following chemotherapy. Further,
knockdown of SOCS1 inmouseDCs or human peripheral blood
mononuclear cells resulted in increased killing of virulentM. tb.
These results indicate that TLR2 andDC-SIGNR1 differentially
regulate SOCS1 expression duringM. tb infection. This in turn
regulatesM. tb survival by governing key cytokine expression.
A major prerequisite toward development of vaccine(s) or
therapeutic regimens for tuberculosis is a thorough under-
standing of the immune responses initiated following infection
of macrophages and DCs by Mycobacterium tuberculosis (M.
tb)2 (1–4). A key factor toward this is cross-regulation of cyto-
kine secretion by different cells of the immune system (5–7).
One of the molecules that regulate cytokine expression and
cytokine receptor-mediated gene expression in various cells of
the immune system is a family of closely related proteins called
Suppressors of Cytokine Signaling (SOCS). There are currently
eight members of SOCS proteins (SOCS1–7 and CIS (also
called SOCS8)), with SOCS1 being the most characterized (8).
All eight SOCS family members have a central Src homology 2
domain, an N-terminal domain of variable length, and a 40-
amino acid motif at the C terminus known as the SOCS box.
Although SOCS molecules exhibit sequence homology, partic-
ularly in the SOCS box and Src homology 2 domains, CIS and
SOCS2, SOCS1 and SOCS3, SOCS4 and SOCS5, and SOCS6
and SOCS7 have marked pairwise homology across the entire
protein sequence. SOCSmolecules bind to the cytoplasmic tails
of cytokine receptors and block their activation. This conse-
quently leads to a block in the effects of the cytokine in question
and leads to skewing of responses.
Although macrophages serve as the long term hosts for
mycobacteria, DCs phagocytose mycobacteria and myco-
bacterial antigens, and these interactions are crucial for the
development of protective immunity (9–11). As a result DC
function and phenotype are modified following bacterial
uptake. A number of surface receptors, e.g.Toll-like receptor
(TLR) 2, mannose receptor, CD11b (Mac-1), CD11c, and
DEC-205 have been implicated in mycobacterial recognition
by DCs, (12–14).
One of the C-type lectin receptors extensively characterized
with respect to mycobacteria is DC-specific ICAM-3 grabbing
non-integrin (DC-SIGN). DC-SIGN has been reported to be
the major receptor on DCs forM. tb (15). DC-SIGN was previ-
ously reported as the receptor forHIVgp120 (16).However, it is
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now demonstrated that DC-SIGN serves as a receptor for a
plethora of pathogens, including viruses (e.g. Ebola, Dengue,
and HIV), bacteria (e.g. M. tb and Salmonella), and parasites
(Leishmania and Plasmodium) (16). Although immature DCs
also express high levels of mannose receptor, CD11b, and
CD11c, neutralizing DC-SIGN with specific antibodies inhib-
ited the interaction of DCs with bothMycobacteria bovis BCG
and mannosylated lipoarabinomannan (manLAM), a major
sugar molecule expressed on the cell surface by virulentMyco-
bacterium sp., by80%. On the other hand neutralizing man-
nose receptor had no significant effect. This indicated that DC-
SIGN binds manLAM in a specific manner.
In the mouse, the “DC-SIGN” locus is much more complex
than in humans and encompasses seven genes coding for
SIGNR1–5 and SIGNR7–8 proteins and one pseudogene cod-
ing for SIGNR6 protein (17). Of these only one gene coding for
mouse DC-SIGN is highly expressed on DCs but not in macro-
phages and lymphocytes. Subsequently, Caminschi et al. (18)
reported the functional comparison of mouse DC-SIGN also
known as CIRE with human DC-SIGN and showed that, like
human DC-SIGN, CIRE or mouse-DC-SIGN bound mannosy-
lated residues but did not bind pathogens known to interact
with human DC-SIGN, including Leishmania mexicana, cyto-
megalovirus, HIV, and lentiviral particles bearing the Ebola
virus glycoprotein. This indicated that the two molecules dis-
played fine specificities with respect to binding partners from
pathogens. Studies by Powlesland et al. (19) also indicated dif-
ferential binding specificities of mouse DC-SIGN homologs to
various ligands. These authors also showed that mouse DC-
SIGN, which they called SIGNR5 and human DC-SIGN, dis-
played similar binding ability to mannose.
manLAM on the other hand has been demonstrated to bind
to many DC-SIGN homologs such as DC-SIGNR1 (CD209b)
and L-SIGN on both mouse and human cells (20) indicating
that this key ligand is important for binding of virulentM. tb to
mouse cells as well. In fact mice lacking DC-SIGNR1 induce
stronger T cell responses toM. tb (21) indicating an inhibitory
role for manLAM in T cell activation. In addition many M. tb
components have been identified as stimulators of TLRs. These
include the 19-kDa lipoprotein and peptidoglycan that act on
TLR2 (22) and the CpG repeat of non-methylated DNA that
acts on TLR9 (23). Interestingly, the interactions ofM. tb vis-a`-
vis TLR and DC-SIGN has shown interesting correlates.
Although interactions with TLR result in activation of DCs
characterized by high IL-12 secretion, interactions with DC-
SIGNprevent DC activation by blockingNF-B activation (24).
For example, TLR9 has been shown to regulate Th1 responses
to M. tb in cooperation with TLR2 (25, 26). However, similar
studies comparing the activities of TLR2 and DC-SIGNR1 in
the mouse system have not been investigated as yet.
In light of the above, in this study, we investigated the inter-
play between SOCS1, DC-SIGNR1, and TLR2 during M. tb
infection and the consequences thereof.We show that stimulat-
ing DC-SIGNR1 on DCs induces expression of SOCS1 and low
IL-12 secretion, whereas stimulating TLR2 results in moderate
SOCS1 expression and high IL-12 levels. Importantly,
DC-SIGNR1 displays greater recruitment of SOCS1 when com-
pared with TLR2. Knockdown of SOCS1 using siRNA not only
results in higher IL-12 expression following DC-SIGNR1 ligation,
but also results in effective killing of intracellular M. tb. Patients
with active disease show increased expression of SOCS1 that
reduce following chemotherapy. These results suggest that differ-
ential regulation of SOCS1 expression and recruitment by TLR2
and DC-SIGNR1 might result in opposite effects from the two
receptors that have a bearing on the survival ofM. tb.
EXPERIMENTAL PROCEDURES
Animals and Human Studies—All experiments were con-
ducted following approval from the institutional animal and
human ethics committees. Female BALB/c mice 4–6 weeks of
age kept in a pathogen-free environment were used. For some
experiments TLR2 knock-out (TLR2/) mice in B6 back-
ground were used. Following informed consent venous blood
was drawn from PPD healthy volunteers or patients in the age
group of 15–60 years freshly diagnosedwith active TB and after
2 months of chemotherapy. Further, either HIV or immuno-
compromised or pregnant women or individuals with a history
of TB were excluded from the study.
Materials—Antibodies to SOCS1, DC-SIGN, DC-SIGNR1,
TLR2, glyceraldehyde-3-phosphate dehydrogenase, and
siRNAs against mouse and human SOCS1 were from Santa Cruz
Biotechnologies. siRNAs to Raf-1 and Syk were obtained from
Dharmacon. Fluorescein isothiocyanate-tagged antibodies to
IFN-R, IL-12R, or IL-10R and enzyme-linked immunosorbent
assay kits were fromBDBiosciences, SanDiego, CA.M. tbH37Rv
mannosylated manLAM was obtained from Tuberculosis
Research Materials and Vaccine Testing, Colorado State Univer-
sity. Details of its preparation can be viewed at on the web. TLR2
ligand Pam3Csk4 was purchased from Invivogen. Acetylated His-
tone 3 ChIP kits were from Upstate Biotechnology, Inc. Lake
Placid, NY.
Generation and Enrichment of DCs and Enrichment of
PBMCs—DCs were differentiated with GM-CSF as described
before (27–30). Briefly, bone marrow from the tibias and
femurs of BALB/c mice were flushed out, and lymphocytes
and I-A cells were depleted following magnet-assisted cell sort-
ing. Cells were cultured in RPMI 1640 medium containing 10%
fetal calf serum, 0.05 M 2-mercaptoethanol, 1 mM sodium pyru-
vate, plus 15ng/mlGM-CSF.HumanPBMCswere enriched from
heparinizedbloodbyFicoll-PaquePlusdensity gradient centrif-
ugation. Splenic DCs from wild-type or TLR2/ mice were
enriched essentially as described earlier. Briefly, spleen from 6–8
micewere pooled and cut into small fragments. From this B andT
cells were removed by incubation with CD19- and CD90-coated
magnet-assisted cell sorting microbeads (Miltenyi). From the
resulting population CD11c DCs were enriched following posi-
tive selection with anti-CD11c antibody-coated magnet-assisted
cell sorting microbeads.
Stimulation of Cells—Unless otherwise mentioned DCs and
PBMCswere stimulatedwith 1g/ml Pam3Csk4 or 5g/mlman-
LAM, and this concentration was considered as high concentra-
tion based on extensive dose titrations (data not shown). In
experiments where DCs were co-stimulated with both the
ligands, the concentrations employed were 0.5 g/ml
Pam3Csk4 and 2.5 g/ml manLAM, and these concentra-
tions were considered as low.
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Infection of Cells with M. tb H37Rv—DCs and PBMCs were
infected with M. tb H37Rv at 1 multiplicity of infection for
different times. Cells were processed either for Western blot-
ting or immunoprecipitation as described below. Alternatively,
cells were processed for monitoring colony forming units.
Transfection of DCs with siRNA—Transfection of DCs with
siRNA was carried out as recently described (30). 5  106/ml
bone marrow precursors were transfected with 60 pmol of
siRNA against SOCS1 for 72 h using the Hiperfect transfection
reagent (Qiagen) inOpti-MEMmedium (Invitrogen). GM-CSF
was added 5 h following transfection, and incubation continued
for 72 h for DC differentiation. Similarly, 2.5 106/ml PBMCs
were transfected with SOCS1 siRNA. Knockdown was verified
by reverse transcription-PCR, following which, cells were
either stimulated with Pam3Csk4 or manLAM or infected with
M. tb. Control siRNAs from Santa Cruz Biotechnology (cata-
logue # sc-37007) and siRNAs to three Plasmodium falciparum
genes Berghepain 1 (BP1), PF10_0348 (P. f DBLMSP), and
PF10_0351 custom synthesized by Dharmacon were used as
nonspecific controls.
Analyses of SOCS1 Levels—SOCS1 levels were monitored
by Western blotting. At the end of incubation, cells were
chilled on ice and washed once with ice-cold phosphate-
buffered saline and lysed in buffer containing 10 mM HEPES
(pH 7.9), 10mMKCl, 0.1mM EDTA, 0.1 M EGTA, 0.5%Nonidet
P-40, and 2 g/ml each of aprotinin, leupeptin, and pepstatin.
The suspensionwas centrifuged at 13,000 rpm for 2min at 4 °C.
The supernatant was designated as the cytoplasmic extract. 25
g of cytoplasmic extract were then resolved on 10% SDS-
PAGE and subsequently transferred onto nitrocellulose mem-
brane (HybondCpure,AmershamBiosciences). The blotswere
then probed with antibodies to SOCS1 followed by horseradish
peroxidase-labeled secondary antibodies. Further, a parallel set
of samples was run separately on SDS-PAGE and probed for
glyceraldehyde-3-phosphate dehydrogenase as loading control.
The blots were later developed by chemiluminescence using
the Luminol reagent.
Immunoprecipitation—Following incubation, cytoplasmic
extracts were prepared as described above. The extracts were
precleared with Protein G-agarose beads, and protein concen-
tration was normalized between samples. The precleared
extracts were then incubated with either anti-DC-SIGN or
anti-DC-SIGNR1, or anti-TLR2 antibodies absorbed to Protein
G-agarose beads, and incubated overnight at 4 °C. The beads
were pelleted and thoroughly washed several times with lysis
buffer. The beads were boiled in SDS-PAGE sample buffer and
resolved on 10% SDS-PAGE followed by Western blotting
against SOCS1 as described above.
FlowCytometry—Cells were stained for surface levels of IFN-
R, IL-12R, or IL-10R using fluorescein isothiocyanate-tagged
antibodies and analyzed by flow cytometry on FACSCalibur
(BD Biosciences). Surface levels of DC-SIGNR1 or TLR2 on
DCs were monitored following biotinylation of anti-DC-
SIGNR1 or anti-TLR2 antibody and subsequent incubation
with DCs, followed by incubation with streptavidin phyco-
erythrin, respectively. The data were plotted using CellQuest
Pro software.
Measurement of Cytokines—Cytokines in the culture super-
natants were measured by employing a sandwich enzyme-
linked immunosorbent assay as described previously (29, 30).
The samples were diluted to obtain absorbance in the linear
range of the standards. In addition, cytokines were also meas-
ured using the Luminex liquichip platform strictly following
the manufacturer’s instructions.
Infection and Drug Treatment of Mice—Infection and drug
treatment of mice were carried out as recently described (29).
Groups of naïvemice (4mice/group)were infectedwith 1 106
M. tbH37Rv via the tail vein. Following 7 days of infectionmice
were treated with oral administration of isoniazid (25 mg/kg
body weight), ethambutol (100mg/kg body weight), and rifam-
picin (20mg/kg bodyweight) essentially as described elsewhere
(31). A repeat dose was given 7 days after and on every alternate
day until the mice were sacrificed.
Statistics—Two-tailed Student’s t test was carried out to
obtain p values. Values of p  0.05 were considered as
significant.
RESULTS
Stimulation of TLR2 and DC-SIGNR1 Induces SOCS1
Expression—To begin with we investigated the levels of SOCS1
expression following stimulation of DC-SIGNR1 and TLR2 on
mouse bone marrow-differentiated DCs. In lieu of the expres-
sion of different homologs of DC-SIGN and related molecules
in mouse cells (32–34), at the onset, we first confirmed that in
our hands DCs differentiated from mouse bone marrow with
GM-CSF indeed express DC-SIGNR1 at both transcript and
surface protein levels (Fig. 1, A and B). The expression levels
were, however, much lower when compared with TLR2.
Next, we stimulated TLR2, with Pam3Csk4, a well character-
ized TLR2 ligand (35) and stimulated DC-SIGNR1 with man-
LAM fromM. tbH37Rv (15, 16, 21) and monitored the expres-
sion of SOCS1. As shown in Fig. 1C, stimulation with either
Pam3Csk4 or manLAM induced the expression of SOCS1. Fig.
1D schematically depicts the average of three experiments
based on densitometric scanning of the blots. Significant differ-
ences were observed between unstimulated and Pam3Csk4
stimulated cells at 24 h (p 0.02), but not in Pam3Csk4-stimu-
lated cells at 6 or 12 h. However, significant differences were
observed between unstimulated andmanLAM-stimulated cells
(p 0.02) at all time points. The collated results of all the blots
thus indicate that, although stimulation of either TLR2 or DC-
SIGNR1 induces the expression of SOCS1, DCSIGNR1 is a
more potent inducer of SOCS1 than TLR2. This is based on
both the kinetics of statistically significant expression, and
because the expression level of TLR2 is much higher than DC-
SIGNR1, quantitatively also, DC-SIGNR1 induces higher
expression of SOCS1 than TLR2.
We next investigated the expression of IL-12p40 and IL-10
following stimulation with Pam3Csk4 andmanLAM. In com-
parison to Pam3Csk4 stimulation, manLAM stimulation
resulted in lower IL-12p40 (supplemental Fig. 1A). Further,
Pam3Csk4 stimulation resulted in low levels of IL-10 expres-
sion. In contrast, IL-10 levels were undetectable upon stimula-
tion with manLAM (supplemental Fig. 1B). In addition, the
expression of a number of pro-inflammatory cytokines and
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chemokines such as IL-6, IP-10, MCP-1, MIP-2, and RANTES
(regulated on activation normal T cell expressed and secreted)
was also higher upon Pam3Csk4 stimulation when compared
with manLAM stimulation (supplemental Fig. 1C).
Co-stimulation of TLR2 and
DC-SIGNR1 Differentially Induces
SOCS1—We next investigated
whether co-stimulating TLR2 and
DC-SIGNR1wouldmodulate SOCS1
in DCs. To this end, we employed
conditions wherein the two recep-
tors would be differentially ligated
depending upon the concentra-
tion of their respective ligands.
So as to achieve measureable ad-
ditive or suppressive effects, we
used different concentrations of
Pam3Csk4 and manLAM to stimu-
late TLR2 and DC-SIGNR1 based
on extensive dose titrations (data
not shown). As shown in Fig. 2A,
individually stimulating DC-SIGNR1
or TLR2 using low concentrations of
manLAM and Pam3Csk4, respec-
tively, resulted in higher SOCS1
expression from DC-SIGNR1 when
compared with TLR2. Once again,
because DCs expressed higher levels
of TLR2 than DC-SIGNR1, this indi-
cated that DC-SIGNR1 stimulation
indeed induced higher SOCS1 ex-
pression when compared with TLR2
stimulation. Next, upon co-sti-
mulating the two receptors using a
high concentration of Pam3Csk4 and
a low concentration of manLAM
(Fig. 2A, p  L (manLAM)), SOCS1
expression was reduced by 50%
when compared with manLAM
alone. In contrast, when the concen-
tration of Pam3Csk4was low and the
concentration ofmanLAMwas high
(p L) or under conditions wherein
both concentrations were low (p 
L), SOCS1 expression was similar to
that obtained with low concentra-
tion of DC-SIGNR1 alone. These
results indicated that expression of
SOCS1 is differentially regulated
following simultaneous ligation of
TLR2 and DC-SIGNR1, with the
latter having a dominating effect
over TLR2 in regulating SOCS1
expression. These results have
important bearings onM. tb infec-
tion wherein multiple receptors
are likely to be simultaneously
triggered.
Stimulation of TLR2 or DC-SIGNR1 with M. tb Infection
Induces Differential Expression of SOCS1 and IL-12—We
extended the above observations and stimulated DCs with
Pam3Csk4 or manLAM along with simultaneous infection with
FIGURE 1.Mouse bone marrow differentiated DCs express TLR2 and DC-SIGNR1 that when stimulated
induce SOCS1 expression. A, reverse transcription-PCR of TLR2 and DC-SIGNR1 mRNA enriched from DCs
differentiated from bone marrow with GM-CSF. B, histograms depicting the relative surface levels of DC-
SIGNR1 (thick line) and TLR2 (thin line) on DCs differentiated from bone marrow with GM-CSF. The shaded
histogramdepicts stainingwith streptavidin-phycoerythrin. ForC, DCswere stimulatedwith1g/ml Pam3Csk4
(Pam) or 5g/mlmanLAM for the indicated times. Post-incubation, cytoplasmic extractswereWesternblotted
for SOCS1. Numbers below the SOCS1 blot indicate relative intensities of the bands. Data from one of three
independent experiments are shown. For D, densitometric values of the three SOCS1 blots were employed to
graphically represent SOCS1 levels in different treatments. Bars represent mean S.D. of the three independ-
ent experiments. NS indicates means between indicated groups were not significant at p 0.05.
FIGURE 2. Co-stimulating TLR2 and DC-SIGNR1 or with M. tb infection differentially modulates SOCS1
expression. A, DCs were stimulated with 0.5 g/ml Pam3Csk4 alone (P) or 2.5 g/ml manLAM (L) alone or
co-stimulated with either equal concentrations of both (P  L) for indicated times. Alternatively, DCs were
stimulated with 1 g/ml Pam3Csk4 and 2.5 g/ml manLAM (P L), or with 0.5 g/ml Pam3Csk4 and 5 g/ml
manLAM(P L) for the indicated times. Post-incubation, cytoplasmic extractswereWesternblotted for SOCS1.
B, DCs were either stimulated with 1 g/ml Pam3Csk4 alone (Pam) or 5 g/ml manLAM alone or co-infected
with 1multiplicity of infectionM. tbH37Rv for the indicated times. Post-incubation, cytoplasmic extracts were
Westernblotted for SOCS1 levels.Numbersbelow theSOCS1blot indicate relative intensities of thebands.Data
from one of three experiments are shown. C, IL-12p40 and IL-10 levels in the culture supernatants from B at
24-h post-stimulation. Data are the mean S.D. of three independent experiments.
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M. tb and monitored SOCS1 expression. As shown in Fig. 2B,
M. tb infection along with Pam3Csk4 (TLR2) stimulation
resulted in a significant reduction of SOCS1 expression when
compared with stimulation of either Pam3Csk4 alone or M. tb
alone.We further confirmed thatM. tb infection did not signif-
icantly alter the expression of TLR2 on DCs (supplemental Fig.
2). This indicated that the reduction in SOCS1 levels upon
stimulating TLR2 along withM. tb infection was not a result of
reduced expression of TLR2. In contrast, no reduction in
SOCS1 levels was obtained upon manLAM (DC-SIGNR1)
stimulation along with M. tb infection, and levels were similar
to that obtained withM. tb alone. These results indicated that,
although TLR2 displays negative cooperativity with M. tb for
SOCS1 expression, DC-SIGNR1 displays positive cooperativity
withM. tb for SOCS1 expression. Further, although stimulation
of TLR2 alone induced higher IL-12p40 levels when compared
with either DC-SIGNR1 orM. tb infection (Fig. 2C), co-stimu-
lation of TLR2 with M. tb infection resulted in a reduction in
IL-12p40 levels when compared with M. tb infection alone.
Likewise, stimulation of DC-SIGNR1 withM. tb infection also
reduced IL-12p40 levels. However, the reduction in IL-12p40
levels wasmuchmore (p 0.04) upon stimulatingDC-SIGNR1
along with M. tb infection. These results indicated that,
although stimulation of TLR2 alone would result in maximum
IL-12 production, simultaneous ligation of other receptors fol-
lowingM. tb infection could attenuate signals from TLR2 thus
reducing IL-12 expression. In contrast, stimulation of
DC-SIGNR1 along with M. tb infection would amplify signals
that result in further reduction in IL-12 expression. No signifi-
cant changeswere observed in IL-10 levels indicating that IL-10
levels are by and large not regulated during co-stimulation of
the above receptors.
Knockdown of SOCS1 in DCs Induces Higher IL-12 from
DC-SIGNR1—Because stimulation of DC-SIGNR1 resulted in
increased SOCS1 expression and lower IL-12p40 expression,
we next investigated, if reduced IL-12 expressionwas a result of
higher SOCS1 expression. To this end, we knocked down
SOCS1 expression in DCs with specific siRNAs and monitored
IL-12p40 levels following stimulation of DC-SIGNR1 and
TLR2. As shown in Fig. 3A, knockdown of SOCS1 in DCs
indeed resulted in higher IL-12p40 expression following DC-
SIGNR1 stimulation. In fact the levels were nearly similar to
those obtained following TLR2 stimulation. Expectedly,
IL-12p40 levels were further increased, albeit marginally, in
these DCs following TLR2 stimulation. We next confirmed the
same at the transcriptional level by monitoring the acetylation
of histoneH3 at the IL-12p40 promoter between position121
to131 (a region that has been functionally characterized to be
important for IL-12 expression) (36), by chromatin immuno-
precipitation in DCs, following knockdown of SOCS1. As
shown in Fig. 3B, compared with DC-SIGNR1 stimulation,
Pam3Csk4 (TLR2) stimulation displayed increased transcrip-
tion at the IL-12p40 promoter as evident from increased pull
downof acetylated histone.However, knockdownof SOCS1 led
to a significant increase in the amplified product upon man-
LAM (DC-SIGNR1) stimulation, indicating regulation of
IL-12p40 at the transcriptional level. This indicated that lower
production of IL-12 from DC-SIGNR1 could be a result of
higher SOCS1 expression.
Raf-1 and Syk Regulate SOCS1 Induction from DC-SIGNR1—
We next investigated mechanism of SOCS1 regulation by DC-
SIGNR1 and TLR2. Although, signal transduction pathways
from DC-SIGN homologs in either mouse or human cells are
not fully characterized, it is reported that human DC-SIGN
modulates IL-10 expression fromTLR4 that involved activation
of the serine and threonine kinase Raf-1 (37). In fact stimulation
of human DC-SIGN alone by manLAM activated Raf-1 in the
absence of TLR4 co-stimulation. Activated Raf-1 increased
acetylation of the p65 subunit of NF-B that resulted in higher
IL-10 from TLR4. Further the same study also pointed to a role
of the Src kinase Syk in the above signaling cascade. Therefore,
we next investigated whether Raf-1 and/or Syk would regulate
SOCS1 in mouse DCs following stimulation of TLR2 or DC-
SIGNR1. To that end we monitored SOCS1 expression in DCs
by the two receptors following Raf-1 and Syk inhibition. As
shown in Fig. 4 (A and B), inhibiting either Raf-1 or Syk signif-
icantly inhibited SOCS1 induction by DC-SIGNR1 in a dose-
dependentmanner indicating a role for Raf-1 and Syk in SOCS1
expression. In contrast, no significant change in SOCS1 expres-
sion was apparent following TLR2 stimulation when Raf-1 was
FIGURE 3. Knockdown of SOCS1 results in higher IL-12p40 expression
from DC-SIGNR1. A, DCs were transfected with siRNAs against SOCS1 and
later stimulated with 1 g/ml Pam3Csk4 (Pam) or 5 g/ml manLAM for 12 h.
MOCK represents no siRNAs (vehicle control), whereas NS1 represents silenc-
ing with nonspecific control siRNAs procured from Santa Cruz Biotechnolo-
gies. NS2 to NS4 represent silencing with nonspecific siRNAs to P. falciparum
genes Berghepain 1 (BP1), PF10_0348 (P. f DBLMSP), and PF10_0351, respec-
tively, custom synthesized byDharmacon. IL-12p40 levels in culture superna-
tants were measured by enzyme-linked immunosorbent assay. Data from
one of three independent experiments are shown. B, chromatin immunopre-
cipitation analysis of acetylated histone H3 (AcH3) from the IL-12p40 pro-
moter in SOCS1-silenced or NS1-silenced DCs stimulated with 1 g/ml
Pam3Csk4 (P) or 5 g/ml manLAM (L) for 12 h. Data from one of three experi-
ments are shown.
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inhibited. However, Syk inhibition resulted in a 2-fold increase
in SOCS1 expression upon TLR2 stimulation, indicating that
Syk played contrasting roles in SOCS1 expression from the two
receptors. To confirm that the effects of the biochemical inhib-
itors were specific, we investigated the same using specific
siRNAs against Raf-1 and Syk. As shown in supplemental Fig. 3,
similar results were obtained when siRNAs were employed
against Raf-1 and Syk. Knockdown of Raf-1 or Syk inhibited
SOCS1 expression from DC-SIGNR1. In contrast Raf-1 inhibi-
tion did not have any significant effect on SOCS1 expression
following TLR2 stimulation, whereas knockdown of Syk
enhanced SOCS1 expression following TLR2 stimulation.
These results confirmed that the results obtained with bio-
chemical inhibitors were specific to Raf-1 and Syk. Next, to see
if the above regulation was dependent or independent of TLR4,
we carried out similar experiments with TLR4/ mice. As
shown in Fig. 4 (C and D), inhibiting Raf-1 indeed down-regu-
lated the expression of SOCS1 from DC-SIGNR1. Further, like
Raf-1, Syk also positively regulated SOCS1 expression from
DC-SIGNR1, because inhibiting Syk significantly inhibited
SOCS1 expression. This indicated that both Raf-1 and Syk reg-
ulated SOCS1 from DC-SIGNR1 independent of TLR4 signal-
ing. Interestingly, Raf-1 also inhibited SOCS1 expression from
TLR2, although the inhibition was less than that observed in
DC-SIGNR1 while Syk played an insignificant role. This
pointed to a role for Raf-1 in SOCS1 expression from TLR2 in
the absence of TLR4.
DC-SIGNR1 Display Increased Association with SOCS1—
SOCS1 has been shown to associate with a number of cytoplas-
mic molecules in addition to cytokine receptors (8). Because
DC-SIGNR1 stimulation increased IL-12p40 expression fol-
lowing knockdown of SOCS1, we investigated whether SOCS1
showed any association with DC-SIGNR1 and TLR2. To this
end we immunoprecipitated TLR2 and DC-SIGNR1 in resting
and Pam3Csk4- and manLAM-stimulated DCs and immuno-
blotted for SOCS1. As shown in Fig. 4E DC-SIGNR1 showed
higher association with SOCS1 when compared with TLR2.
These results together with the results in Fig. 3 strongly indi-
cated that lower IL-12 levels from
DC-SIGN could be a result of its
increased association with and
induced expression of SOCS1.
PBMCs of Patients with Active TB
Disease ExpressHigher SOCS1—We
next extended the above observa-
tions to human cells in the context
of M. tb infection. We first con-
firmed that DC-SIGN is expressed
in PBMCs (data not shown). Next,
we monitored SOCS1 expression in
PBMCs of PPD healthy asymp-
tomatic individuals, patients with
active TB disease, and the same
patients following 2 months of
chemotherapy. Twelve patients
consented to give blood samples for
the study, and 8 patients consented
to be bled again following 2 months
of therapy. Fig. 5A depicts a repre-
sentative profile from one of many
similar profiles. PBMCs of patients
with active TB disease showed
much higher expression of SOCS1
when compared with healthy in-
dividuals. However, following 2
FIGURE 4. DC-SIGNR1 induces SOCS1 expression via Raf-1 and Syk and
SOCS1 associateswithDC-SIGNR1. A and B, SOCS1 levels in DCs stimulated
with 1g/ml Pam3Csk4 (Pam) or 5g/mlmanLAM for 24 h in the presence or
absence of 5M and 10M GW5074 a Raf-1 inhibitor (Raf-1-inhib) or 5g/ml
and 10 g/ml piceatannol, a Syk inhibitor (Syk-inhib). For C and D, DCs from
TLR4/mice were processed as in A and B. For E, either TLR2 or DC-SIGNR1
were immunoprecipitated from DCs following stimulation with 1 g/ml
Pam3Csk4 (Pam) or 5 g/ml manLAM for the indicated times and Western
blotted for SOCS1.Numbersbelow the SOCS1blot indicate relative intensities
of the bands. Data from one of three independent experiments are shown.
FIGURE 5. Patients with active TB disease express high SOCS1 that is associated with DC-SIGN and reg-
ulated by Raf-1 and Syk. A, SOCS1 levels in PBMCs of healthy individual or patient with active TB disease and
the samepatient after 2months of chemotherapy (Follow-up) following stimulationwith 1g/ml Pam3Csk4 (P)
or 5g/mlmanLAM (L) for 24 h. One of eight similar blots is shown. For B, densitometric values of SOCS1 blots
of all the healthy controls, patients, and follow-ups were employed to graphically represent SOCS1 levels in
different cohorts. Bars represent mean  S.D. of SOCS1 levels in each cohort irrespective of the treatment
employed. C, PBMCs from a patient with active TB disease were simulated with 1 g/ml Pam3Csk4 (Pam) or 5
g/mlmanLAM for 24h. Cytoplasmic extractswere immunoprecipitatedwith either anti-TLR2or anti-DC-SIGN
antibody andWestern blotted for SOCS1.D and E, SOCS1 levels in PBMCs of healthy individual stimulatedwith
1 g/ml Pam3Csk4 (Pam) or 5 g/ml manLAM for 24 h in the presence or absence of 5 M and 10 M GW5074
a Raf-1 inhibitor (Raf-1-inhib) or 5 g/ml and 10 g/ml piceatannol, a Syk inhibitor (Syk-inhib). One of three
independent experiments is shown.
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months of chemotherapy, SOCS1 levels were reduced to those
observed in healthy individuals. A schematic of SOCS1 levels in
all the healthy controls, patients with active TB, and their fol-
low-ups screened based on densitometric scans of the blots is
depicted in Fig. 5B. These results indicate that SOCS1 expres-
sion positively correlated with the severity of the TB disease.
Further, similar to DC-SIGNR1, SOCS1 in human PBMCs also
showed increased association with DC-SIGN, when compared
with TLR2 (Fig. 5C) pointing to a similar mechanism of down-
regulation of pro-inflammatory responses fromDC-SIGN. Fur-
thermore, like DC-SIGNR1, SOCS1 expression by DC-SIGN in
human PBMCs was also regulated by Raf-1 and Syk (Fig. 5, D
and E), wherein inhibition of either Raf-1 or Syk resulted in a
significant inhibition of SOCS1 expression upon eitherTLR2or
DC-SIGN stimulation. These results indicated that DC-SIGN-
mediated regulation of SOCS1 was similar in both mouse and
human cells. However, in contrast tomouseDCs, Syk positively
regulated SOCS1 expression from TLR2.
TLR2 and DC-SIGN Modulate Expression of Cytokines and
Cytokine Receptors—Because the levels of cytokines and their
receptors are modulated at different stages of M. tb infection
(38) we next investigated the roles played by TLR2 and DC-
SIGN to this end. As shown in Fig. 6, TLR2 stimulation resulted
in higher IL-12p40 expression in all three cohorts when com-
pared with DC-SIGN stimulation. This could result from
increased association of SOCS1 with DC-SIGN when com-
pared with TLR2. On the other hand stimulation of DC-SIGN
induced significantly higher IL-10 expression in all the three
cohorts, especially in patients with active disease when com-
paredwith TLR2 stimulation. Further, it has been reported that
PBMCs of healthy individuals express higher IFN- receptor
when compared with PBMCs from patients with active TB dis-
ease (38). We therefore investigated if TLR2 and DC-SIGN
wouldmodulate the levels of IFN-, IL-12, and IL-10 receptors.
As shown in Fig. 7, PBMCs from healthy individuals expressed
higher IFN- and IL-12 receptor levels than TB patients that
were significantly increased following TLR2 stimulation, but
not upon DC-SIGN stimulation. IL-10 receptor levels were by
and large not different between any groups or treatment. These
results demonstrate that TLR2 and DC-SIGN play a role in
mediating the levels of pro-inflammatory cytokines and their
receptors that might be modulated by their differential associ-
ations with SOCS1.
DC-SIGNR1 Stimulation Induces Higher SOCS1 Expression
in TLR2/ DCs—We next extended the observations on
human cells to TLR2/ mice. It is well established that
TLR2/ mice are more susceptible to M. tb infection than
wild-type mice (39, 40) and would thus simulate an active TB
disease phenotype of human patients. We therefore, investi-
gated SOCS1 expression in splenic DCs from M. tb-infected
TLR2/ mice and also from infected and drug-treated mice.
As shown in Fig. 8A, stimulating DC-SIGNR1 in TLR2/DCs
induced a 2-fold higher SOCS1 expression when compared
with TLR2 stimulation. The weak increase in SOCS1 expres-
sion following stimulation of TLR2/ DCs with Pam3Csk4
could result from engagement of TLR1 by Pam3Csk4. It has
been reported that Pam3Csk4 binds to both TLR2 and TLR1,
although with a much higher affinity to TLR2 (35). Neverthe-
less, increased SOCS1 expression following DC-SIGNR1 stim-
ulation in TLR2/DCs indicated that, with an increase in the
severity of the disease, SOCS1 showed higher expression via
DC-SIGNR1. Significantly, SOCS1 expression from DC-
SIGNR1 in DCs from drug cured TLR2/-infected mice was
reduced to background levels (Fig. 8B). These results are in
concurrence with the results observed in human patients,
FIGURE 6.TLR2 stimulation induceshigh IL-12p40expression inPBMCsof healthy individuals andTBpatients. IL-12p40 (A) and IL-10 (B) levels in culture
supernatants of PBMCs fromhealthy individuals, patientswith active TBdisease andpatients after 2months of chemotherapy (followup) following stimulation
with 1g/ml Pam3Csk4 for 12 h (Pam 12h) or 1g/mlmanLAM for 24 h. Control depicts levels in unstimulated PBMCs. Each spot represents data from a single
individual. Bars in the graphs indicate median within the samples.
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wherein SOCS1 expression was
higher during TB disease and come
down following chemotherapy.
Knockdown of SOCS1 Results in
IncreasedKilling ofM. tb inDCs and
PBMCs—In the light of the above
data it was relevant to investigate
the effects of SOCS1 knockdown on
the survival of M. tb in DCs and
PBMCs. siRNA-mediated knock-
down of SOCS1 resulted in a signif-
icant reduction in M. tb colony
forming units in both mouse DCs
(Fig. 8C, p  0.04) and human
PBMCs (Fig. 8D, p  0.03), when
compared with nonspecific con-
trols. These results emphasize the
negative role of SOCS1 inmediating
protective responses toM. tb.
DISCUSSION
It is now recognized that stimula-
tion of specific receptors on DCs (as
also on other cell types) effectively
determines the way an immune
response is tailored to a given
pathogen. This is true for pathogens
such asM. tb, which has successfully
devised numerous ways to evade
protective responses mounted by a
highly evolved immune system (7).
This includes down-regulation of
cellular activation and antigen
presentation pathways by specific
antigens resulting in suppressor
responses (22). Over the years we
have also highlighted the role of M.
tb antigens in modulating DC func-
tion. These antigen-activated DCs
not only down-regulate pro-inflam-
matory responses to M. tb (Ref. 24
and reviewed in Ref. 42) but also
serve as depots for mycobacterial
survival by modulating key intracel-
lular signaling molecules. Condi-
tioning DCs with appropriate cyto-
kines and chemokines resulted in
mounting of protective responses
and the clearance of an established
M. tb infection in mice (29).
With respect to DCs, TLR2 and
DC-SIGN are the two receptors that
play crucial roles with contrasting
outcomes (24). This is more true for
human DCs, because not much
information is known inmouse cells
owing to the complex nature of DC-
SIGN related molecules expressed
FIGURE 7. TLR2 stimulation increases IL-12 receptor levels on PBMCs. Surface levels of IFN- receptor
(IFN-R (A)), IL-121 receptor (IL-12R (B)), and IL-10 receptor (IL-10R (C)) in PBMCs of healthy individuals
(closed bars) and patients with active TB disease (open bars) stimulated with 1 g/ml Pam3Csk4 or 5 g/ml
manLAM for 24 h. Control depicts levels in unstimulated PBMCs. Data are represented as Relative Mean
Fluorescence Intensity (MFI). Bars represent mean  S.D. of five healthy and five TB patients. In A: *, p 
0.05 (for unstimulated PBMCs of healthy versus patients and manLAM-stimulated cells of healthy versus
patients) and **, p  0.01 (for Pam3Csk4-stimulated cells of healthy versus patients). In B, *, p  0.05 (for
Pam3Csk4-stimulated cells of healthy versus patients), ns depicts differences in the mean are not
significant.
FIGURE 8. DCs from M. tb-infected TLR2/ mice show high SOCS1 expression upon DC-SIGNR1
stimulation and knockdown of SOCS1 kills intracellularM. tb. A, SOCS1 levels in splenic DCs fromM. tb
H37Rv-infected wild-type and TLR2/mice following stimulation with 1 g/ml Pam3Csk4 (P) or 5 g/ml
manLAM (L) for 24 h. For B, wild-type and TLR2/ mice were infected with M. tb H37Rv for 2 weeks
followed by drug treatment. SOCS1 levels in splenic DCs were later monitored as in A. One of three
experiments is shown. C and D,M. tb H37Rv colony forming units in mouse DCs (C) and human PBMCs (D)
following knockdown of SOCS1 with specific siRNAs. MOCK represents no siRNA (vehicle control), while
NS1 represents silencing with nonspecific control siRNAs procured from Santa Cruz Biotechnologies. NS2
toNS4 represent silencingwith nonspecific siRNAs to P. falciparum genes Berghepain 1 (BP1), PF10_0348 (P.
f DBLMSP), and PF10_0351, respectively, custom synthesized by Dharmacon. Data are the mean S.D. of
three independent experiments.
SOCS1 Regulates Immunity toM. tuberculosis
SEPTEMBER 18, 2009•VOLUME 284•NUMBER 38 JOURNAL OF BIOLOGICAL CHEMISTRY 25539
 by guest on M
arch 29, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
in mouse cells (17–21). Major outcomes of TLR2 stimulation
are the activation of NF-B, and the consequent expression of
pro-inflammatory cytokines such as tumor necrosis factor-
and IL-12p40. IL-12p40 plays a key role in mediating type 1
(Th1) responses from DCs, a crucial factor that determines
resistance or susceptibility toM. tb infection and disease (7, 25,
26). On the other hand, DC-SIGN stimulation results in block-
ade of TLR-mediated NF-B activation and IL-12 expression.
However, the mechanisms that mediate these differential
effects are not yet outlined, possibly owing to the fact that signal
transduction pathways from DC-SIGN and its mouse ho-
mologs are not yet fully characterized.
A key regulator of cytokine production and activation and in
turn the regulator of Th1/Th2 responses is SOCS. The role of
SOCS molecules during inflammation and infection are well
characterized. SOCS1/ neonates are hyper-responsive to
lipopolysaccharide, and very sensitive to lipopolysaccharide-
induced lethality. In addition, BCG infection induces the pro-
duction of SOCS1 and SOCS3 inmousemacrophages (43). Fur-
ther, trehalose 6,6	-dimycolate/cord factor, amajor component
of theM. tb cell wall, induces expression of SOCS and inhibits
IFN--stimulated phosphorylation of signal transducers and
activators of transcription 1.
In the light of the above, in this study, we investigated the role
of SOCS1 in DC activation by TLR2 and DC-SIGNR1, because
it has been shown that DC-SIGNR1 negatively regulates Th1
responses toM. tb (21). We show that, although stimulation of
TLR2 or DC-SIGNR1 induces SOCS1 expression, DC-SIGNR1
induces SOCS1 with faster kinetics. Additionally, because DC-
SIGNR1 levels are much lower when compared with TLR2 lev-
els, the data indicated that, in effect, DC-SIGNR1 induces
higher SOCS1 expression. This was further confirmed when
the two receptors were co-stimulated with different concentra-
tions of their ligands, wherein SOCS1 was expressed at higher
levels when DC-SIGNR1 was the dominant trigger. More
importantly, triggering the two receptors in the context ofM. tb
infection, to simulate a physiological scenario, resulted in a pos-
itive synergy between DC-SIGNR1 and M. tb for SOCS1
expression. In contrast SOCS1 expression was lowered when
TLR2 was triggered along with M. tb infection. The relative
levels of IL-12, a key cytokine that polarizes DCs to induce Th1
responses also negatively correlated with SOCS1 expression.
This was confirmed when knockdown of SOCS1 using siRNA
resulted in enhanced IL-12 transcription and translation fol-
lowing DC-SIGNR1 stimulation. This clearly indicated that
DC-SIGNR1 induces suppressor responses duringM. tb infec-
tion via enhanced expression of SOCS1.
Importantly, SOCS1 was observed to associate with DC-
SIGNR1, whereas its association with TLR2 was minimal. This
indicated that it is not only the relative expression of SOCS1 by
the two triggers that regulates IL-12 production; it is also the
subcellular localization that plays an important role. In effect it
also indicated that amajor blockade in signaling ofDC-SIGNR1
toward IL-12 expression was mediated by its association with
SOCS1. Although the inhibitory effects of DC-SIGNR1 during
M. tb infection have been well known, the one or more precise
mechanisms by which these effects are mediated are not fully
understood. We show that one of the mechanisms by which
these effects could be modulated is by regulation of SOCS1
expression that subsequently leads to regulation of IL-12 pro-
duction, a crucial cytokine formounting protective pro-inflam-
matory responses from DCs. Several mechanisms have been
proposed for the suppression of cytokine production by SOCS1
(43). A direct effect of SOCS1 on the TLR-NF-B pathway has
been proposed. SOCS1 binds to the p65 subunit of NF-B and
facilitates ubiquitylation and degradation of p65 (44). SOCS1
also binds to tyrosine phosphorylated MAL (myeloid differen-
tiation primary-response gene 88 (MyD88)-adaptor-like
protein, also known as TIRAP) through its interaction with
Bruton’s tyrosine kinase and induces ubiquitylation and degra-
dation of MAL, thereby leading to the suppression of MAL-de-
pendent p65 phosphorylation and transactivation of NF-B
(45). In addition to the NF-B pathway, SOCS1 also regulates
the stress-activated MAPKs, Jun N-terminal kinase (JNK), and
p38 by binding to apoptosis signal-regulating kinase 1, which is
an upstream activator of both the JNK and p38MAPK cascades
(41).
It has been demonstrated that Raf-1 is activated following
stimulation of DC-SIGN with manLAM (37). Activated Raf-1
regulates IL-10 expression from TLR4 that further involves the
Src tyrosine kinase Syk and the transcription factorNF-B.Our
results on mouse DCs provide an additional pathway wherein
Raf-1 and Syk regulate DC-SIGNR1-mediated expression of
SOCS1 that in turn regulates IL-12 expression. Importantly,
this pathway functions in the absence of TLR signaling indicat-
ing that DC-SIGNR1 on its own could suppress pro-inflamma-
tory signals via SOCS1.
We next extended the above results to human cohorts and
showed that SOCS1 expression increased with the severity of
TB disease such that patients with active TB disease displayed
higher SOCS1 levels. More importantly, with the clearance of
infection following chemotherapy, SOCS1 levels returned to
baseline. The profiles of cytokines and their receptors on
PBMCs also correlatedwell with SOCS1 expression and disease
phenotype. This clearly indicated that SOCS1 played a crucial
role in modulating immune responses toM. tb infection at dif-
ferent stages. We simulated the human results in a mouse
model using TLR2/mice that are highly susceptible toM. tb
infection and could represent the TB disease phenotype
observed in human patients. In concurrence with the human
data, DC-SIGNR1 stimulation resulted in higher SOCS1
expression in TLR2/ DCs fromM. tb-infected mice. Signifi-
cantly,DCs from infected anddrug-curedmice did not enhance
SOCS1 expression following DC-SIGNR1 stimulation. This
clearly indicated that with the severity of disease as represented
in patients with active TB disease, the expression of SOCS1 is
increased following DC-SIGN stimulation.
The above results add support to the hypothesis proposed by
van Kooyk and Geijtenbeek (16), wherein at initial stages of
infection when the pathogen load is low, TLR2 triggering
induces protective immunity and prevents the development of
active TB disease. Following increased bacterial burden and the
development of active disease, as a result of HIV infection or
other factors (7), solublemanLAMsecreted from infectedmac-
rophages triggers DC-SIGN to induce suppressor responses
that favor the pathogen that includes increased secretion of
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IL-10 and lowproduction of IL-12.Our results presented in this
study indicate that increased expression of SOCS1 could be one
of the suppressor molecules that contribute toward induction
of these responses via regulation of IL-12 and IL-12 receptor
levels. Our data on increased IL-12 production following
knockdown of SOCS1 by RNA interference, and the resultant
killing ofM. tb insideDCs as well as PBMCs adds support to the
hypothesis and establishes the negative role of SOCS1 during
M. tb infection and disease.
Put together, the results presented in the study have identi-
fied a novel mechanism by which the contrasting effects of
TLR2 and DC-SIGNR1 on DCs duringM. tb infection are reg-
ulated. This includes regulation of SOCS1 expression and its
subcellular localization. The subsequent regulation of cytokine
and cytokine receptor expression during various stages ofM. tb
infection and disease as a result of high expression of SOCS1
further points to a negative role played by this molecule during
M. tb infection.
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